United States: DOJ Complaint Names Private Equity Firm As Defendant In False Claims Act Case Targeting Health Care Portfolio Company

The U.S. Department of Justice's recent decision to name a private equity firm as a defendant in a False Claims Act complaint against one of the firm's portfolio companies, while uncommon, shines a spotlight on potential risk areas for private equity firms whose portfolio companies operate in industries with significant False Claims Act exposure like health care. In its complaint in intervention in United States ex rel. Medrano v. Diabetic Care Rx, LLC d/b/a Patient Care America et al. (S.D. Fla. No. 15-62617-civ), filed on February 16, 2018, DOJ alleges that compounding pharmacy Patient Care America ("PCA") paid illegal kickbacks to several marketing firms in exchange for referrals for certain compound drugs that were reimbursed by Tricare, a federal health care program that provides health insurance for current military personnel, military retirees, and their dependents. The complaint further alleges that the pharmacy's controlling stakeholder, private equity firm Riordan, Lewis & Haden, Inc. ("RLH"), managed and controlled PCA and participated in the charged misconduct. The government's intervention to target both PCA and its private equity shareholder reflects a potential sea change in its approach to such cases. 

The Scheme Alleged in the Complaint in Intervention and RLH's Involvement 

The DOJ's complaint against PCA arises from an alleged marketing scheme involving compound topical pain creams. PCA, a compounding pharmacy previously focused on providing intravenous nutrition to patients with end-stage kidney disease, changed course in early 2014 and entered the compound pain cream business. Allegedly, Tricare reimbursement rates for pain cream products were known to be unusually high at the time. 

In service of PCA's compounding pain cream initiative, the complaint alleges, PCA entered into independent contractor agreements with three marketing companies, under which each company would target and refer patients—specifically Tricare beneficiaries—to PCA for compounded drug prescriptions. PCA compensated the marketing companies exclusively via commissions: the marketers received 50% of PCA's profits from each referred prescription. Over time, referrals from the marketing companies accounted for the vast majority of PCA's total compounding revenue. And because these referrals were generally concentrated among Tricare beneficiaries, reimbursements from Tricare for the pain creams also came to make up a substantial proportion of PCA's profits. 

The complaint alleges that PCA's commission payments to the marketing firms were illegal kickbacks under the Federal Anti-Kickback Statute ("AKS"), and that the claims resulting from these kickbacks were presented to Tricare for payment by PCA in violation of the FCA. Specifically, the complaint alleges that the marketers provided services and were paid commissions by PCA as independent contractors, which did not qualify for employment safe harbor protection under the AKS. The complaint also alleges additional misconduct, including that marketers paid kickbacks to patients by covering copayments regardless of financial need, in order to secure and fill additional prescriptions. Finally, the complaint alleges that the marketers also paid telemedicine physicians to write prescriptions without patient consent and without establishing legitimate physician-patient relationships. The complaint alleges that, as a result of the marketing scheme and related misconduct, PCA ultimately received more than $68 million in reimbursement for compound pain and other topical creams. 

The complaint alleges that private equity firm RLH was not only deeply involved in the strategy and management of PCA, but also that it exerted considerable influence over a number of the bad acts described in the complaint. The allegations focus on two RLH partners, Michel Glouchevitch and Kenneth Hubbs, who also served as officers of the co-defendant pharmacy. 

Per the complaint, RLH invested in PCA in July 2012, and planned to increase the company's value so that PCA could be sold at a profit after five years. Shortly after RLH's initial investment, however, Medicare reimbursement rates for PCA's core business at the time dropped considerably, and PCA's revenue fell accordingly. The complaint alleges that RLH, led by Glouchevitch and Hubbs, initiated and championed PCA's entry into the pain cream business in order to make use of "the extraordinarily high profitability of this therapy" and generate a "quick and dramatic payback" on its investment. The complaint quotes RLH documents that recognized that overcharging for products in the pain management business risked "cross[ing] the line from an ethics standpoint." In service of the pain cream venture, RLH is alleged to have played a significant role in the staffing and oversight of PCA. For example, after initiating PCA's entry into the pain cream market, Glouchevitch then recommended that PCA hire Patrick Smith as CEO against the advice of RLH's own consultant. 

With respect to the specific violations alleged, the complaint makes both general and specific claims of knowledge on the part of RLH. It alleges that RLH, based on its extensive experience investing in the health care industry, was well-versed in the Anti-Kickback Statute and related laws and regulations, including the obligation of PCA to make a good faith attempt to determine patients' financial condition before waiving copayments. The complaint goes further, however, alleging that at a relatively early point, RLH and PCA were specifically advised by outside counsel that PCA should not be submitting claims to Tricare for prescriptions referred by marketers because of potential anti-kickback concerns. 

Finally, the complaint alleges that RLH participated in the scheme by periodically funding the commission payments to the marketing firms when those payments were due before PCA had received the corresponding Tricare reimbursements. The complaint alleges that RLH was aware that this money was used to pay marketing commissions. 

Medrano is pending in the District Court for the Southern District of Florida.

Considerations for Private Equity Firms in the Health Care Industry

While much remains to be seen regarding how this case will play out in litigation, and it may prove to be an outlier on its facts, Medrano potentially signals a new frontier for DOJ in pursuing FCA cases and provides some clues as to the type of conduct that DOJ may consider in deciding issues of authority and control when assessing FCA liability. Accordingly, private equity firms should consider the following when investing in and operating portfolio companies in the Health Care industry: 

  • Level of Involvement: It is common for private equity firms to have representatives serving on the boards of directors of portfolio companies. Where a private equity firm is the majority or sole stakeholder in a portfolio company, it is important to take into account the extent to which the firm is involved in shaping operations and decisions at the portfolio company level. The DOJ's approach in the Medrano case suggests that a private equity firm's risk of an allegation of False Claims Act liability may increase with the degree of involvement in the portfolio company's day-to-day operations. Accordingly, private equity firms may wish to consider drawing clear lines of demarcation in corporate policies and agreements relating to actions taken by individuals in their capacities as directors, officers, and stockholder representatives of portfolio companies. Also, to the extent that private equity firms provide services to portfolio companies, they may wish to consider providing such services through separate organizations that are distinct from the firm's investment funds.
  • Monitoring and Compliance of Portfolio Company Activity: Particularly in industries where False Claims Act liability is significant, private equity firms should consider development of robust monitoring and compliance programs at the portfolio company level. This type of initiative establishes the "tone from the top" and evidences the intent of the investors and board leadership to ensure that the portfolio company has appropriate internal legal support and compliance staffing, including training for the portfolio managers with primary responsibility for overseeing and supporting the company's operations.
  • Board and Committee Participation: Specific to board-level oversight, firms should consider forming a compliance-focused subcommittee on a portfolio company's board of directors. The subcommittee can be tasked with ensuring compliance with internal policies and implementation of the compliance program consistent with industry guidance and standards.
  • Advice of Counsel and Advisors: Medrano underscores the importance of obtaining and following the advice of counsel and consultants on matters involving potential False Claims Act liability. A robust portfolio company compliance program with the type of committee reporting structure described above would provide a forum for consideration of advice from counsel and other advisors on risks material to the business.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions